Metagenomi TherapeuticsvsMerck & Company

MGX and MRK stock compared: price, dividend, valuation and results, from SEC filings.

MGX

Metagenomi Therapeutics, Inc.

$0.66

Value $25M

+4.44%
MGX's page

MRK

Merck & Company, Inc.

$139.07

Value $344B

-3.04%
MRK's page

Metagenomi Therapeutics (MGX) has a market value of $25M and Merck & Company (MRK) $344B. Over the last year, with dividends, MGX moved -61.2% and MRK +54.2%. Dividend yield: MGX none, MRK 2.44%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MGX$25M

    MRK$344B

    MRK is 13,860 times MGX

  • Revenue, 12 months

    MGX$7.1M

    MRK$67.4B

    MRK is 9,509 times MGX

  • Net income, 12 months

    MGX-$94M

    MRK$2.5B

  • Operating margin

    MGX-1,410.6%

    MRK–

  • ROIC

    MGX-58.0%

    MRK3.9%

    61.9 points apart

  • P/E

    MGX–

    MRK140.2

  • Dividend yield

    MGX0.0%

    MRK2.4%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MGX-61.2%

MRK+54.2%

50100150DecFebAprJunAugOct
Returns by period
PeriodMGXWith dividendsMRKWith dividends
1 year since November 17, 2025-61.2%Price -61.2%+54.2%Price +49.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MGXMetagenomi TherapeuticsMRKMerck & Company

Valuation

MGXMRK
Valuation
Price$0.66$139.07
Market value$25M$344B
Enterprise value (EV)–$388B
P/E–140.2
P/E, 5-year median–14.8
P/B0.37.7
EV/EBIT–81.5
Free cash flow yield–4.3%

Results and growth

MGXMRK
Results and growth
Revenue, 12 months$7.1M$67.4B
Net income, 12 months-$94M$2.5B
Free cash flow, 12 months-$84M$14.7B
Earnings per share, 12 months-$2.50$0.98
Revenue growth, year on year-51.8%1.3%
Revenue growth a year, past-25.0%over 2 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

MGXMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin-1,410.6%–
Net margin-1,329.3%3.6%
ROIC-58.0%3.9%
ROE-69.2%5.2%

Balance sheet

MGXMRK
Balance sheet
Cash$102M$9.7B
Total debt$36M$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

MGXMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–3.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MGX or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Metagenomi Therapeutics or Merck & Company?

By market value, Merck & Company ($344B) is about 13,860.4 times Metagenomi Therapeutics ($25M), at today's prices.

How did MGX and MRK stock do over the last 1 years?

Since November 17, 2025, MGX's price moved -61.2% and MRK's +49.8%. With dividends: MGX -61.2% (-61.2% a year), MRK +54.2% (+54.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, MGX or MRK?

The dividend yield at today's price is none for Metagenomi Therapeutics and 2.44% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Metagenomi Therapeutics or Merck & Company?

Over the last twelve months, the net margin was -1,329.3% for Metagenomi Therapeutics and 3.6% for Merck & Company, and the operating margin -1,410.6% and –. Revenue was $7.1M and $67.4B.

Which is the better investment, Metagenomi Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.